Additionally, some other factors, such as different study design (prospective versus retrospective), tumor KRAS/BRAF/PIK3CA mutation status that affected the survival of CRC patients should also be attributed to some of the heterogeneity. This evidence concerns the gene KRAS and neoplasm.